By Katherine Hamilton
A change in Medicare policy is expected to flatten revenue from Gilead Science's HIV products, one of its most profitable segments.
The biopharmaceutical company anticipates reforms to Medicare Part D, a voluntary prescription drug coverage, will lop off $1.1 billion of its 2025 revenue with almost $900 million coming from HIV products. As a result, HIV revenue for the year is expected to be flat with 2024 at about $19.6 billion. Gilead estimates HIV product sales would have increased 5% in 2025 if it weren't for the added costs from the Medicare reforms.
The reforms are mandated by the Inflation Reduction Act and require Medicare prescription drug plans to allow enrollees to use capped monthly installments to pay for out-of-pocket prescription drugs.
It also requires drug manufacturers to provide discounts for patients during initial coverage and catastrophic phases, as well as for people who qualify for the low-income subsidy $(LIS.AU)$ program. LIS users are disproportionately impacted by HIV, Gilead said, which is why the change would have such a major impact on that business.
The HIV segment went a long way in boosting Gilead's earnings, with its product sales climbing 16% in the fourth quarter. Higher demand and volume made it the most profitable segment in the past quarter, and offset decreasing sales for its Covid-19 treatment.
Shares of Gilead were up 7% to $103.27 on Wednesday, at one point touching a 52-week high of $104.71, after fourth-quarter earnings and outlook beat Wall Street's expectations.
Write to Katherine at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
February 12, 2025 12:13 ET (17:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。